BioPharma Resources

Drug Trial Radar · NCT05419635

A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function

Investigation of the Influence of Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Asundexian in Participants With Mild or Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function.

Last checked: Nov 19, 2026Latest source record: Aug 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Jun 14, 2022

Primary completion

May 24, 2023

Study completion Aug 21, 2023

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jun 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to prevent the formation of blood clots in people who have or have had: * an irregular and often rapid heartbeat * a blocked blood flow to the heart * a blocked or reduced blood flow to a part of the brain. When a blood clot forms in the body in patients with the above conditions, it may block vessels of the heart, the brain and/or other parts of the body. This may lead to heart attack, stroke and other serious complications. Blood clots are formed in a process known as coagulation. This is a complex series of steps that must occur in a specific sequence. Medications are already available to prevent the formation of blood clots. They work by interrupting one or more of the coagulation steps and are therefore known as anticoagulants. They decrease the risk of the above-mentioned complications. The study treatment asundexian works by blocking a very specific step in the blood clotting process, the activation of a protein called Factor XIa. Due to its very specific action that is not thought to be involved in the main blood clotting steps needed to stop bleeding (e.g. like from a cut finger), asundexian is expected to reduce the risk of bleeding that is still seen with existing anticoagulants. Since people who need an anticoagulant may also have liver problems, information on asundexian use in this group is needed. The main purpose of this study is to learn how asundexian moves into, through and out of the body in participants with a mild or moderate reduction in liver function compared to participants with normal liver function who are similar in age, weight, and gender. To answer this question, researchers will measure * the average highest level of asundexian in the blood (also referred to as Cmax) * the average total level of asundexian in the blood (also referred to as AUC). that were reached after intake of a single tablet of asundexian. The researchers will compare these data between participants with reduced liver function and matched participants with normal liver function to look for differences. Each participant will be in the study for up to 4 weeks. Participants will stay in-house for 6 days, starting the day before taking asundexian. In addition, two visits to the study site are planned. During the study, the doctors and their study team will: * do physical examinations * check vital signs * take blood and urine samples * examine heart health using an electrocardiogram (ECG) * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

Conditions

  • Prevention of Thromboembolic Events
  • Atrial Fibrillation
  • Acute Myocardial Infarction
  • Non-cardioembolic Ischemic Stroke
  • Hepatic Impairment

Interventions

  • Asundexian (BAY2433334)Drug

    Study intervention BAY2433334 will be administered as tablet taken orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration vs. time curve from zero to infinity after single dose (AUC)*of BAY2433334Time frame: 0 - 96 hours post dose
  2. Area under the concentration vs. time curve in plasma from zero to infinity (AUCu)* (unbound) after a single dose of BAY2433334.Time frame: 0 - 96 hours post dose
  3. Maximum observed drug concentration (Cmax) after single dose administration of BAY2433334.Time frame: 0 - 96 hours post dose
  4. Maximum observed drug concentration (Cmax,u) (unbound) after a single dose of BAY2433334.Time frame: 0 - 96 hours post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CRS-Kiel

    Kiel, Schleswig-Holstein, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.